Vancomycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vancomycin: From Gram-Positive Bacterial Infections to Diffuse Scleroderma
One-Sentence Summary
Vancomycin is a glycopeptide antibiotic with an established clinical role in treating serious Gram-positive bacterial infections (e.g., MRSA), a use referenced repeatedly in this Evidence Pack’s mechanistic analyses even though it is not captured in the record’s structured indication fields. The TxGNN model assigns its highest prediction score (99.92%) to Diffuse Scleroderma, but this association is currently supported by only 1 case report and no clinical trials — and that single report describes a drug-related allergic rash, not therapeutic efficacy. Evidence quality is at the lowest tier (L5), and the pipeline’s own scoring recommends Hold.
Note: This Evidence Pack screened 10 candidate indications for Vancomycin. Among them, streptococcal pneumonia (rank 9) is substantially better supported (L3, “Proceed with Guardrails”) because it aligns with vancomycin’s already-established role in treating penicillin-resistant S. pneumoniae. The top-ranked candidate featured below is simply the single highest TxGNN score in the pack, not the strongest repurposing hypothesis overall — see Conclusion for detail.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in structured fields (original_indications and licenses are both empty in this record). Vancomycin’s established clinical use — serious Gram-positive bacterial infections, e.g., MRSA — is referenced throughout the evidence pack’s mechanistic rationale text. |
| Predicted New Indication | Diffuse Scleroderma |
| TxGNN Prediction Score | 99.92% (rank 1,889 overall) |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is marked as a data gap (DG002) in this record. Based on the pharmacological class information embedded in this Evidence Pack’s own rationale text, Vancomycin is a glycopeptide antibiotic that inhibits bacterial peptidoglycan (cell wall) synthesis, giving it activity restricted to Gram-positive organisms.
Diffuse scleroderma is an autoimmune connective-tissue disease with no infectious pathophysiology. The pack’s own repurposing rationale states explicitly: “對自體免疫結締組織疾病（硬皮症）無已知機轉關聯” — there is no known mechanistic link between Vancomycin’s cell-wall-synthesis-inhibition activity and autoimmune fibrotic disease.
The only supporting literature (PMID 31541072) is a case report of a drug-associated exfoliative rash with sepsis and eosinophilia, i.e., an adverse-reaction narrative, not evidence of therapeutic benefit in scleroderma. This pattern is consistent with a TxGNN knowledge-graph co-occurrence artifact rather than a biologically grounded repurposing hypothesis, and it explains why the pipeline’s own scoring stage already flags the recommendation as Hold.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31541072 | 2019 | Case Report | The American Journal of Case Reports | Describes a 56-year-old man with diffuse exfoliative rash, sepsis, and eosinophilia following antibiotic treatment (including vancomycin exposure history). Reports a suspected drug hypersensitivity/adverse reaction — not a treatment outcome for scleroderma. |
India Market Information
No CDSCO/India market authorizations are on file for Vancomycin in this record (market_status: Not Marketed; total_licenses: 0).
Safety Considerations
Drug Interactions: A DDI query returned 454 total interactions on file. Selected examples from the returned set:
- Major-level: Human immunoglobulin G (intravenous); Human botulinum neurotoxin A/B immune globulin; Vibrio cholerae CVD 103-HgR strain live antigen (live)
- Moderate-level: Ketorolac, Ibuprofen, Diclofenac, Celecoxib (NSAIDs); Amikacin, Capreomycin, Amphotericin B/Amphotericin B (lipid complex) (nephrotoxicity-related co-administration); Ethinylestradiol, Estradiol; Metformin; Carboplatin; Bacitracin; Mesalazine, Balsalazide; Ibandronate; Cholestyramine
Label-level warnings and contraindications are not available in this record (blocked by data gap DG001 — see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (diffuse scleroderma) has no mechanistic plausibility, no clinical trial evidence, and a single supporting citation that describes an adverse drug reaction rather than efficacy — evidence level L5. A blocking data gap (DG001: no TFDA/CDSCO label warnings or contraindications on file) also prevents this candidate from entering the S1 safety pre-screen regardless of efficacy evidence.
To proceed, the following is needed:
- Official product label / package insert data (warnings, contraindications) to close blocking gap DG001
- Formal DrugBank MOA confirmation to close gap DG002
- If pursuing repurposing evaluation for Vancomycin further, prioritize re-review of streptococcal pneumonia (rank 9 in this pack), which already carries L3 evidence and a “Proceed with Guardrails” recommendation grounded in existing clinical practice (vancomycin as an established option for penicillin-resistant S. pneumoniae)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.